This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kurtz, C. B.
Right arrow Articles by Klinger, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kurtz, C. B.
Right arrow Articles by Klinger, J. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2001, p. 2340-2347, Vol. 45, No. 8
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.8.2340-2347.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

GT160-246, a Toxin Binding Polymer for Treatment of Clostridium difficile Colitis

Caroline B. Kurtz,1,* E. Pat Cannon,1,dagger Alex Brezzani,1 Mary Pitruzzello,1 Carol Dinardo,1 Emilie Rinard,1 David W. K. Acheson,2 Richard Fitzpatrick,1 Pamela Kelly,1 Keith Shackett,1 Andrew T. Papoulis,1 Philip J. Goddard,1 Robert H. Barker Jr.,1 Gerard P. Palace,1 and Jeffrey D. Klinger1

GelTex Pharmaceuticals, Inc., Waltham, Massachusetts 02451,1 and Tufts University/New England Medical Center, Boston, Massachusetts 021112

Received 5 January 2001/Returned for modification 27 February 2001/Accepted 23 April 2001

GT160-246, a high-molecular-weight soluble anionic polymer, was tested in vitro and in vivo for neutralization of Clostridium difficile toxin A and B activities. Five milligrams of GT160-246 per ml neutralized toxin-mediated inhibition of protein synthesis in Vero cells induced by 5 ng of toxin A per ml or 1.25 ng of toxin B per ml. In ligated rat ileal loops, 1 mg of GT160-246 neutralized fluid accumulation caused by 5 µg of toxin A. At doses as high as 80 mg/loop, cholestyramine provided incomplete neutralization of fluid accumulation caused by 5 µg of toxin A. GT160-246 protected 80% of the hamsters from mortality caused by infection with C. difficile, whereas cholestyramine protected only 10% of animals. Treatment of C. difficile-infected hamsters with metronidazole initially protected 100% of the hamsters from mortality, but upon removal of treatment, 80% of the hamsters had relapses and died. In contrast, removal of GT160-246 treatment did not result in disease relapse in the hamsters. GT160-246 showed no antimicrobial activity in tests with a panel of 16 aerobic bacteria and yeast and 22 anaerobic bacteria and did not interfere with the in vitro activities of most antibiotics. GT160-246 offers a novel, nonantimicrobial treatment of C. difficile disease in humans.

* Corresponding author. Mailing address: GelTex Pharmaceuticals, Inc., 153 Second Ave., Waltham, MA 02451. Phone: (781) 434-3477. Fax: (781) 895-4980. E-mail: ckurtz{at}geltex.com.

dagger Present address: Paratek Pharmaceuticals, Inc., Boston, MA 02111.

Antimicrobial Agents and Chemotherapy, August 2001, p. 2340-2347, Vol. 45, No. 8
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.8.2340-2347.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Williams, O. M., Spencer, R. C. (2009). The management of Clostridium difficile infection. Br Med Bull 91: 87-110 [Abstract] [Full Text]  
  • Baines, S. D., Freeman, J., Wilcox, M. H. (2009). Tolevamer Is Not Efficacious in the Neutralization of Cytotoxin in a Human Gut Model of Clostridium difficile Infection. Antimicrob. Agents Chemother. 53: 2202-2204 [Abstract] [Full Text]  
  • Monaghan, T, Boswell, T, Mahida, Y R (2009). Recent advances in Clostridium difficile-associated disease. Postgrad. Med. J. 85: 152-162 [Abstract] [Full Text]  
  • Hinkson, P. L., Dinardo, C., DeCiero, D., Klinger, J. D., Barker, R. H. Jr. (2008). Tolevamer, an Anionic Polymer, Neutralizes Toxins Produced by the BI/027 Strains of Clostridium difficile. Antimicrob. Agents Chemother. 52: 2190-2195 [Abstract] [Full Text]  
  • Monaghan, T, Boswell, T, Mahida, Y R (2008). Recent advances in Clostridium difficile-associated disease. Gut 57: 850-860 [Abstract] [Full Text]  
  • Surowiec, D., Kuyumjian, A. G, Wynd, M. A, Cicogna, C. E (2006). Past, Present, and Future Therapies for Clostridium difficile-Associated Disease. The Annals of Pharmacotherapy 40: 2155-2163 [Abstract] [Full Text]  
  • Voth, D. E., Ballard, J. D. (2005). Clostridium difficile Toxins: Mechanism of Action and Role in Disease. Clin. Microbiol. Rev. 18: 247-263 [Abstract] [Full Text]  
  • van Dissel, J. T, de Groot, N., Hensgens, C. M., Numan, S., Kuijper, E. J, Veldkamp, P., van 't Wout, J. (2005). Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J Med Microbiol 54: 197-205 [Abstract] [Full Text]  
  • Louie, T. J., Meddings, J. (2004). Clostridium difficile infection in hospitals: risk factors and responses. CMAJ 171: 45-46 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»